Editor-in-Chief Emeritus Pick of Papers
Free access for our readers
For each issue of Radiotherapy and Oncology, the Editor-in-Chief Emeritus Jens Overgaard, picks his favourite papers.
- Radical cystectomy with cisplatin-based neoadjuvant chemotherapy is considered the standard of care to treat localized urothelial muscle-invasive bladder carcinoma (MIBC), providing 5-year overall survival (OS) rates of more than 50% among fit patients [1,2].
- A typical fractionated radiotherapy (RT) course is a long and arduous process, demanding significant financial, physical, and mental commitments from patients. RT plans are usually delivered over the course of several weeks, and in most cases have long-term and even life-long consequences on patients’ quality of life after treatment. Each additional session of RT significantly increases the physical and psychological burden on patients and leads to higher radiation exposure in organs-at-risk (OAR), while, in some cases, the therapeutic benefits might not be high enough to justify the risks.
- Dose escalated radiotherapy improves outcomes for men with prostate cancer. A plateau for benefit from dose escalation using EBRT may not have been reached for some patients with higher risk disease. The use of increasingly conformal techniques, such as step and shoot IMRT or more recently VMAT, has allowed treatment intensification to be achieved whilst minimising associated increases in toxicity to surrounding normal structures. To support further safe dose escalation, the uncertainties in the treatment target position will need be minimised using optimal planning and image-guided radiotherapy (IGRT).